Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ACXP Acurx Pharmaceuticals	$0.48 -15.4%	$0.42	$0.30 ▼ $3.33	$13.30M	-1.38	1.64 million shs	1.22 million shs
MTVA MetaVia	$0.68 +0.1%	$0.73	$0.63 ▼ $5.30	$13.31M	0.18	144,993 shs	35,441 shs
NXTC NextCure	$0.46 -1.3%	$0.47	$0.22 ▼ $1.82	$13.07M	1.07	125,577 shs	117,779 shs
SPRC SciSparc	$0.31 -4.4%	$0.31	$0.20 ▼ $1.79	$3.59M	0.72	4.15 million shs	385,713 shs

The 10 Best AI Stocks to Own in 2025

Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ACXP Acurx Pharmaceuticals	-15.40%	-33.46%	+21.60%	+17.31%	-78.61%
MTVA MetaVia	+0.10%	-2.86%	-11.94%	-56.96%	+67,999,900.00%
NXTC NextCure	-1.31%	+1.63%	-6.50%	-8.00%	-71.25%
SPRC SciSparc	-4.38%	+2.45%	0.00%	-0.71%	-65.64%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ACXP Acurx Pharmaceuticals	3.0022 of 5 stars	3.5	5.0	0.0	2.7	1.7	0.0
MTVA MetaVia	2.0418 of 5 stars	3.5	0.0	0.0	2.0	0.0	1.3
NXTC NextCure	4.5806 of 5 stars	3.5	5.0	4.3	2.0	1.7	1.3
SPRC SciSparc	0.798 of 5 stars	0.0	5.0	0.0	1.8	0.0	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ACXP Acurx Pharmaceuticals	3.00	Buy	$8.00	1,569.80% Upside
MTVA MetaVia	3.00	Buy	$7.50	1,002.94% Upside
NXTC NextCure	3.00	Buy	$3.50	660.87% Upside
SPRC SciSparc	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest SPRC, MTVA, NXTC, and ACXP Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/19/2025	MTVA MetaVia	Maxim Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$6.00 ➝ $3.00
5/15/2025	ACXP Acurx Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy	$8.00
4/16/2025	MTVA MetaVia	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$12.00 ➝ $12.00

(Data available from 6/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	$0.03 per share	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	$0.92 per share	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	$2.34 per share	N/A
SPRC SciSparc	$1.31M	2.62	N/A	N/A	$0.86 per share	0.36

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ACXP Acurx Pharmaceuticals	-$14.10M	-$0.70	N/A	N/A	N/A	N/A	-526.78%	-223.78%	8/8/2025 (Estimated)
MTVA MetaVia	-$27.59M	N/A	0.00	N/A	N/A	N/A	-222.13%	-123.85%	8/13/2025 (Estimated)
NXTC NextCure	-$55.65M	-$1.76	N/A	N/A	N/A	N/A	-70.16%	-58.10%	7/30/2025 (Estimated)
SPRC SciSparc	-$6.28M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A

Latest SPRC, MTVA, NXTC, and ACXP Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	MTVA MetaVia	-$0.57	-$0.36	+$0.21	-$0.36	N/A	N/A
5/12/2025	Q1 2025	ACXP Acurx Pharmaceuticals	-$0.14	-$0.11	+$0.03	-$0.11	N/A	N/A
5/1/2025	Q1 2025	NXTC NextCure	-$0.40	-$0.39	+$0.01	-$0.39	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ACXP Acurx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
MTVA MetaVia	N/A	N/A	N/A	N/A	N/A
NXTC NextCure	N/A	N/A	N/A	N/A	N/A
SPRC SciSparc	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ACXP Acurx Pharmaceuticals	N/A	1.93	1.93
MTVA MetaVia	N/A	1.55	1.55
NXTC NextCure	N/A	10.26	10.26
SPRC SciSparc	N/A	5.36	5.28

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ACXP Acurx Pharmaceuticals	11.53%
MTVA MetaVia	1.37%
NXTC NextCure	42.65%
SPRC SciSparc	25.06%

Insider Ownership

Company	Insider Ownership
ACXP Acurx Pharmaceuticals	26.00%
MTVA MetaVia	0.80%
NXTC NextCure	17.90%
SPRC SciSparc	1.52%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ACXP Acurx Pharmaceuticals	3	23.48 million	17.38 million	Optionable
MTVA MetaVia	8	19.59 million	19.43 million	N/A
NXTC NextCure	90	28.05 million	23.03 million	Optionable
SPRC SciSparc	4	11.23 million	11.06 million	Not Optionable

SPRC, MTVA, NXTC, and ACXP Headlines

Recent News About These Companies

SciSparc Announces 1-for-21 Reverse Share Split - Morningstar

June 26 at 11:28 AM | morningstar.comM

SciSparc Ltd. Adjourns Annual Meeting Due to Lack of Quorum

June 25 at 1:23 PM | msn.com

SciSparc Ltd: SciSparc Announces 1-for-21 Reverse Share Split

June 25 at 7:56 AM | finanznachrichten.de

SciSparc Ltd. Announces One-for-Twenty One Reverse Share Split Effective July 3, 2025

June 24 at 5:41 PM | quiverquant.comQ

SciSparc Announces 1-for-21 Reverse Share Split

June 24 at 5:03 PM | globenewswire.com

SciSparc (NASDAQ:SPRC) Stock Price Down 0.8% - Here's What Happened

June 21, 2025 | americanbankingnews.com

SciSparc secures Japanese patent for pain relief combo

May 28, 2025 | investing.com

SciSparc Unveils Japanese Patent for Novel Pain Relief Combination

May 27, 2025 | tipranks.com

SciSparc Ltd. Announces Publication of Novel Japanese Patent for Enhanced Pain Management Therapy Combining Paracetamol and PEA

May 27, 2025 | quiverquant.comQ

SciSparc Announces Publication of Japanese Patent Application

May 27, 2025 | globenewswire.com

SciSparc Ltd. Announces European Patent Application for Cocaine Addiction Treatment in Collaboration with Clearmind Medicine Inc.

May 13, 2025 | nasdaq.com

SciSparc and Clearmind Secure European Patent for Cocaine Addiction Therapy

May 13, 2025 | tipranks.com

SciSparc-Clearmind Collaboration Leads to Publication of European Patent for Psychedelic-Based Combination Therapy for Cocaine Addiction

May 12, 2025 | uk.finance.yahoo.com

SciSparc announces collaboration with Clearmind Medicine

April 26, 2025 | markets.businessinsider.com

Scisparc and Clearmind Push into Eating Disorder And Addiction Treatment With New Patents

April 25, 2025 | theglobeandmail.com

SciSparc and Clearmind File Patent for Eating Disorder Treatment

April 25, 2025 | tipranks.com

SciSparc-Clearmind Collaboration Leads to Filing of International Patent Application for Novel Treatment of Anorexia, Bulimia and other Eating Disorders

April 25, 2025 | globenewswire.com

SciSparc Extends Deadline for Miza III Ventures Deal

April 1, 2025 | tipranks.com

SciSparc Ltd. Extends Merger Agreement with AutoMax Motors

April 1, 2025 | tipranks.com

SciSparc files to sell 61.21M ordinary shares for holders

March 26, 2025 | markets.businessinsider.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SPRC, MTVA, NXTC, and ACXP Company Descriptions

Acurx Pharmaceuticals NASDAQ:ACXP

$0.48 -0.09 (-15.40%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.49 +0.01 (+2.69%)

As of 04:46 AM Eastern

Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections. The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections. It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia. Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.

MetaVia NASDAQ:MTVA

$0.68 +0.00 (+0.10%)

As of 06/26/2025 04:00 PM Eastern

MetaVia Inc. is a clinical-stage biotechnology company focused on transforming cardiometabolic diseases. MetaVia Inc., formerly known as NeuroBo Pharmaceuticals Inc., is based in CAMBRIDGE, Mass.

NextCure NASDAQ:NXTC

$0.46 -0.01 (-1.31%)

Closing price 06/26/2025 04:00 PM Eastern

Extended Trading

$0.46 +0.00 (+0.43%)

As of 06/26/2025 07:47 PM Eastern

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. The company is developing NC410, an immunomedicine designed to block immune suppression mediated by LAIR-1; NC762, a monoclonal antibody that binds specifically to B7-H4, a protein expressed on multiple tumor types; and NC525, a monoclonal antibody that binds to LAIR-1 to functionally kill AML blast cells and leukemic stem cells while preserving normal blood cells, including hematopoietic stem cells. Its discovery and research programs include an antibody in preclinical evaluation of other potential novel immunomodulatory molecules. It has a license agreement with Yale University. The company was incorporated in 2015 and is headquartered in Beltsville, Maryland.

SciSparc NASDAQ:SPRC

$0.31 -0.01 (-4.38%)

Closing price 06/26/2025 03:56 PM Eastern

Extended Trading

$0.31 +0.00 (+1.37%)

As of 04:42 AM Eastern

SciSparc Ltd., a clinical-stage pharmaceutical company, develops drugs based on cannabinoid therapies. Its drug development programs include SCI-110 for the treatment of Tourette syndrome and Alzheimer's disease and agitation; SCI-160 for the treatment of pain; SCI-210 for the treatment of autism spectrum disorder and status epilepticus; and CannAmide, an anti-inflammatory and chronic pain solution. The company has an agreement with Procaps to develop and commercially manufacture SCI-110 and CannAmide, a palmitoylethanolamide oral tablet in softgel capsule form. It also has an agreement with The Israeli Medical Center for Alzheimer's to conduct a phase IIa clinical trial to evaluate the safety, tolerability, and efficacy of SCI-110 in patients with Alzheimer's disease and agitation; and a collaboration with Clearmind Medicine Inc. The company was formerly known as Therapix Biosciences Ltd. and changed its name to SciSparc Ltd. in January 2021. SciSparc Ltd. was incorporated in 2004 and is headquartered in Tel Aviv-Yafo, Israel.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time